Login
Search
Search
0 Dates
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
A New Era in Cardio-Oncology: Uprising Heart Failure Therapies for Cardio-Permissive Strategies in Cancer Therapy-Related Cardiac Dysfunction
Session:
SESSÃO DE POSTERS 11 - CARDIONCOLOGIA DE PONTA II
Speaker:
Leonor Magalhães
Congress:
CPC 2025
Topic:
D. Heart Failure
Theme:
10. Chronic Heart Failure
Subtheme:
10.6 Chronic Heart Failure - Clinical
Session Type:
Cartazes
FP Number:
---
Authors:
Leonor Magalhães; Ricardo Carvalheiro; Isabel Cardoso; Vera Vaz Ferreira; Tânia Branco Mano; Luís Almeida Morais; Boban Thomas; Rui Cruz Ferreira
Abstract
<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Aptos,sans-serif"><span style="font-size:10.0pt"><span style="font-family:"Calibri",sans-serif">Permissive cardiotoxicity is a novel concept in cardio-oncology that balances the need for life saving oncological therapy with the acceptance of its cardiotoxicity. One of the most feared cardiotoxicities of chemotherapy (QT) is cancer therapy-related cardiac dysfunction (CTRCD) which often leads to premature QT discontinuation. Change in left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS) define the CTRCD according to 2022 ESC Cardio-oncology guidelines.</span></span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Aptos,sans-serif"><strong><span style="font-size:10.0pt"><span style="font-family:"Calibri",sans-serif">Methods: </span></span></strong><span style="font-size:10.0pt"><span style="font-family:"Calibri",sans-serif">Retrospective analysis of outpatients (P) diagnosed with CTRCD, followed at a cardio-oncology clinic at a tertiary centre between April 2021 and December 2023, managed with a permissive cardiotoxicity strategy without subsequent QT discontinuation.</span></span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Aptos,sans-serif"><strong><span style="font-size:10.0pt"><span style="font-family:"Calibri",sans-serif">Results: </span></span></strong><span style="font-size:10.0pt"><span style="font-family:"Calibri",sans-serif">20P were included with a mean age of 56±12 years, 80% were women. Most common malignancies were breast cancer (65%) and hematologic neoplasms (25%); 45% were stage IV. The major of cardiotoxic QT were HER2-targets (55%) and anthracyclines (15%). There was a high burden of CV risk factors (≥2 in 55%). The median follow-up was 16 months (IQR 11-27).</span></span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Aptos,sans-serif"><span style="font-size:10.0pt"><span style="font-family:"Calibri",sans-serif">Most patients (85%) presented mild or moderate asymptomatic CTRCD. The cohort presented a median baseline of LVEF 61% (IQR 58-65) and GLS -17.5% (-15.2 to -18.2%). Both presented a significant decrease during QT to a median minimum LVEF of 49% (p<0.001) and GLS -13.9% (p=0.028). A increase in NT-proBNP levels (median 2x increase) was observed in 9 (45%), with a median maximum of 1805 pg/mL. Only 3P experienced mild-to-moderate symptomatic HF due to toxicity, 1 requiring hospitalization.</span></span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Aptos,sans-serif"><span style="font-size:10.0pt"><span style="font-family:"Calibri",sans-serif">All patients received cardioprotective therapy (95% under ≥2 HF pillar classes; 25% under sacubitril-valsartan). With permissive strategy, 13P (65%) completed the entire oncological treatment, with a post-treatment median LVEF of 57% (53–61) and GLS of -15.2% (-15.5-18.2%), showing no significant difference compared to baseline (p>0.05). 7P remain on QT, 6 of whom are under palliative treatment despite cardiac dysfunction for over 12 months (range: 14 to 36 months). No mortality or severe cardiovascular-related adverse events were reported. </span></span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Aptos,sans-serif"><strong><span style="font-size:10.0pt"><span style="font-family:"Calibri",sans-serif">Conclusion </span></span></strong><span style="font-size:10.0pt"><span style="font-family:"Calibri",sans-serif">A permissive cardiotoxicity strategy supported by optimized cardiac care and close monitoring allowed patients with mild-to-moderate CTRCD to safely maintain QT with cardioprotective therapy. These findings underscore the importance of structured cardio-oncology follow-up in enabling high-risk patients to complete oncological therapies.</span></span></span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site